Related Experiment Video
Updated: Mar 13, 2026

Shock Wave Application to Cell Cultures
Published on: April 8, 2014
Low-Intensity Extracorporeal Shock Wave Therapy in Vascular Disease and Erectile Dysfunction: Theory and Outcomes
Ilan Gruenwald1, Noam D Kitrey1, Boaz Appel1
1Neuro-Urology Unit, Rambam Healthcare Campus, Haifa, Israel; Department of Urology, Sheba Medical Center, Ramat-gan, Israel.
Low-intensity extracorporeal shock wave therapy (LI-ESWT) shows promise for treating erectile dysfunction (ED) by promoting neovascularization and improving penile blood flow. Clinical data suggest LI-ESWT can restore erectile function in both PDE5i responders and non-responders.
Area of Science:
- Urology
- Regenerative Medicine
- Biomedical Engineering
Background:
- Erectile dysfunction (ED) is a prevalent condition affecting men's health.
- Low-intensity extracorporeal shock wave therapy (LI-ESWT) is an emerging treatment for ED.
- Vasculogenic ED requires novel therapeutic approaches.
Approach:
- Systematic literature review on LI-ESWT mechanisms.
- Clinical data analysis of LI-ESWT efficacy in men with vasculogenic ED.
- Medline database search utilizing relevant keywords.
Key Points:
- LI-ESWT mechanism likely involves neovascularization, enhancing corporal blood flow.
- LI-ESWT improved erectile function in 60-75% of patients previously responsive to PDE5 inhibitors.
- LI-ESWT enabled 72% of PDE5 inhibitor non-responders to achieve vaginal penetration.
Conclusions:
- LI-ESWT demonstrates potential for long-term improvement and restoration of erectile function.
- The therapy may permanently restore erectile function by improving penile hemodynamics.
- Further multi-centered studies are warranted to validate these promising findings.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Peripheral Artery Disease III: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Antihypertensive Drugs: Vasodilators

